Table S1. Search strategies and results Table S2. Quality assessment of the included studies (NOS) Figure S1. Forest plot of AT-DILI risk associated with rs2001350 polymorphism in NFE2L2<
Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market because of inability to identify potential patients prior to clinic
The incidence of drug induced liver injury (DILI) increased in recent years. Since most DILI are idiosyncratic which has obvious individual differences and genetic predisposition, so research on genet
Drug-Induced-Liver-Injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market because of inability to identify potential patients prior to clinic
Table A. Information of primers and probes. Table B. IL-6, STAT3 and HSPA1L Polymorphisms in Patients with and without ATDH (unmatched case-control study). Table C. ORs and 95% CIs for ATDH in relatio